Medroxyprogesterone acetate

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

1959

www.ebi.ac.uk

First approval year: 1959
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Medroxyprogesterone acetate
www.ebi.ac.uk

Molecular weight: 386.53
www.ebi.ac.uk

Structure (SMILES): CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
www.ebi.ac.uk

adgyn medro
Adgyn medro
amen
Amen
climanor
Climanor
curretab
Curretab
cycrin
Cycrin
depo progevera
depo provera
depo provera oncology
depo subq provera 104
Depo-progevera
Depo-provera
Depo-provera oncology
Depo-subq provera 104
farlutal
Farlutal
farlutal 100
Farlutal 100
farlutal 200
Farlutal 200
farlutal 250

And 15 more, listed on the interactive page.

17 hydroxy 6α methylpregn 4 ene 3 20 dione acetate
17-Hydroxy-6α-methylpregn-4-ene-3,20-dione acetate
conjugated estrogens 0 45 mg medroxyprogesterone acetate 1 5 mg
Depo Provera
Depo-Provera
depot medroxyprogesterone acetate
Depot medroxyprogesterone acetate
Depot medroxyprogesterone acetate (DMPA)
Depot Medroxyprogesterone Acetate 150 mg
Depot-medroxyprogesterone acetate
dmpa
DMPA
farlutal inyectable
Farlutal inyectable
g03ac06
G03AC06
intramuscular depot medroxyprogesterone acetate
Intramuscular DMPA
lunelle component medroxyprogesterone acetate
LUNELLE COMPONENT MEDROXYPROGESTERONE ACETATE
medroxiprogesterona
Medroxiprogesterona
medroxyprogesterone
Medroxyprogesterone
Medroxyprogesterone - Acetate

And 63 more, listed on the interactive page.

CAS registry numbers

71-58-9

ChEMBL ID: CHEMBL717
www.ebi.ac.uk

InChIKey: PSGAAPLEWMOORI-PEINSRQWSA-N
www.ebi.ac.uk

PubChem compound IDs

6279

FDA ingredient codes (UNII)

C2QI4IOI2G

G03AC06
G03DA02
L02AB02

Sources for recorded values

www.ebi.ac.uk

6691
1000112

Applicant: PFIZER
Approval date: 18 Jun 1959
Application number: NDA011839

Patents: 0
Designations: 1
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Pharmacology name: medroxyprogesterone
Type: Synthetic organic
Drug name stem: -gest-; -ster-; -terone

Administration routes

Oral
Parenteral

Mechanisms of action

Mechanism
Progesterone receptor agonist
Action type
Agonist
Target
Progesterone receptor
Protein identifier
P06401

Open Targets mechanisms

Mechanism
Progesterone receptor agonist
Action type
Agonist
Target
Progesterone receptor

DrugCentral mechanisms

Action type
Agonist
Gene symbol
PGR
Protein identifier
P06401
Organism
Homo sapiens
Target development level
Clinical

Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000180
Subject identifier
D015658
Condition
Cardiovascular Diseases
Highest recorded phase
3
Condition identifier
EFO:0000319
Subject identifier
D002318
Condition
Diabetes Mellitus
Highest recorded phase
3
Condition identifier
EFO:0000400
Subject identifier
D003920
Condition
Hyperplasia
Highest recorded phase
4
Condition identifier
EFO:0000536
Subject identifier
D006965
Condition
Hypertension
Highest recorded phase
3
Condition identifier
EFO:0000537
Subject identifier
D006973
Condition
Infertility
Highest recorded phase
3
Condition identifier
EFO:0000545
Subject identifier
D007246
Condition
Neoplasms
Highest recorded phase
4
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Prostatic Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000673
Subject identifier
D011471
Condition
Carcinoma, Renal Cell
Highest recorded phase
4
Condition identifier
EFO:0000681
Subject identifier
D002292
Condition
HIV Infections
Highest recorded phase
2
Condition identifier
EFO:0000764
Subject identifier
D015658
Condition
Endometriosis
Highest recorded phase
4
Condition identifier
EFO:0001065
Subject identifier
D004715
Condition
Coronary Disease
Highest recorded phase
3
Condition identifier
EFO:0001645
Subject identifier
D003327
Condition
Carcinoma, Renal Cell
Highest recorded phase
4
Condition identifier
EFO:0002890
Subject identifier
D002292
Condition
Pregnancy
Highest recorded phase
1
Condition identifier
EFO:0002950
Subject identifier
D011247
Condition
Heart Diseases
Highest recorded phase
3
Condition identifier
EFO:0003777
Subject identifier
D006331
Condition
Pain
Highest recorded phase
2
Condition identifier
EFO:0003843
Subject identifier
D010146
Condition
Sleep Apnea Syndromes
Highest recorded phase
2
Condition identifier
EFO:0003877
Subject identifier
D012891
Condition
Osteoporosis
Highest recorded phase
3
Condition identifier
EFO:0003882
Subject identifier
D010024
Condition
Endometrial Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0004230
Subject identifier
D016889
Condition
Bone Diseases
Highest recorded phase
3
Condition identifier
EFO:0004260
Subject identifier
D001847
Condition
Myocardial Ischemia
Highest recorded phase
3
Condition identifier
EFO:1001375
Subject identifier
D017202
Condition
Menopause
Highest recorded phase
3
Condition identifier
GO:0042697
Subject identifier
D008593
Condition
Menorrhagia
Highest recorded phase
3
Condition identifier
HP:0000132
Subject identifier
D008595
Condition
Hypercholesterolemia
Highest recorded phase
3
Condition identifier
HP:0003124
Subject identifier
D006937
Condition
Primary Ovarian Insufficiency
Highest recorded phase
2
Condition identifier
HP:0008209
Subject identifier
D016649

And 9 more, listed on the interactive page.

Condition identifier
EFO_0000180
Highest recorded phase
2
Condition identifier
EFO_0000536
Condition identifier
EFO_0000545
Highest recorded phase
3
Condition identifier
EFO_0000616
Condition identifier
EFO_0000764
Highest recorded phase
2
Condition identifier
EFO_0001065
Condition identifier
EFO_0002890
Condition identifier
EFO_0002950
Condition identifier
EFO_0002950
Highest recorded phase
1
Condition identifier
EFO_0003777
Highest recorded phase
3
Condition identifier
EFO_0003877
Condition identifier
EFO_0003882
Highest recorded phase
3
Condition identifier
EFO_0004230
Highest recorded phase
2
Condition identifier
EFO_0004714
Condition identifier
EFO_0009520
Highest recorded phase
1
Condition identifier
EFO_0009520
Highest recorded phase
3
Condition identifier
GO_0030728
Highest recorded phase
1
Condition identifier
GO_0042697
Highest recorded phase
1
Condition identifier
GO_0042697
Highest recorded phase
3
Condition identifier
HP_0000132
Highest recorded phase
3
Condition identifier
HP_0000789
Highest recorded phase
3
Condition identifier
HP_0008209
Highest recorded phase
2
Condition identifier
HP_0012531
Highest recorded phase
2
Condition identifier
HP_0031217
Highest recorded phase
3
Condition identifier
MONDO_0002050

And 32 more, listed on the interactive page.

Warning
Black Box Warning
Effect
carcinogenicity
Warning
Black Box Warning
Effect
cardiotoxicity
Warning
Black Box Warning
Effect
musculoskeletal toxicity
Warning
Black Box Warning
Effect
neurotoxicity
Warning
Black Box Warning
Effect
respiratory toxicity
Warning
Black Box Warning
Effect
vascular toxicity

Warning
Black Box Warning
Effect
carcinogenicity
Country
United States
Warning
Black Box Warning
Effect
cardiotoxicity
Country
United States
Warning
Black Box Warning
Effect
musculoskeletal toxicity
Country
United States
Warning
Black Box Warning
Effect
neurotoxicity
Country
United States
Warning
Black Box Warning
Effect
respiratory toxicity
Country
United States
Warning
Black Box Warning
Effect
vascular toxicity
Country
United States

Event
abortion spontaneous
Reports
119
Reporting signal score
125.032
Event
amenorrhoea
Reports
89
Reporting signal score
187.894
Event
asthma
Reports
121
Reporting signal score
98.0166
Event
back pain
Reports
175
Reporting signal score
77.5802
Event
breast cancer
Reports
179
Reporting signal score
318.352
Event
breast cancer female
Reports
53
Reporting signal score
123.972
Event
breast cancer in situ
Reports
25
Reporting signal score
76.9293
Event
breast cancer metastatic
Reports
37
Reporting signal score
69.5324
Event
breast tenderness
Reports
33
Reporting signal score
74.9207
Event
bursitis
Reports
113
Reporting signal score
295.288
Event
butterfly rash
Reports
25
Reporting signal score
83.2702
Event
clear cell renal cell carcinoma
Reports
24
Reporting signal score
80.4989
Event
coeliac disease
Reports
118
Reporting signal score
374.493
Event
drug hypersensitivity
Reports
288
Reporting signal score
144.363
Event
erythema
Reports
164
Reporting signal score
83.1372
Event
fibrocystic breast disease
Reports
21
Reporting signal score
67.9433
Event
fluid retention
Reports
118
Reporting signal score
153.462
Event
food allergy
Reports
113
Reporting signal score
383.848
Event
hepatic enzyme increased
Reports
121
Reporting signal score
104.446
Event
hot flush
Reports
92
Reporting signal score
90.4565
Event
hyperhidrosis
Reports
158
Reporting signal score
112.996
Event
hypersensitivity
Reports
257
Reporting signal score
212.1
Event
immunodeficiency
Reports
109
Reporting signal score
315.09
Event
injection site abscess
Reports
66
Reporting signal score
213.273
Event
injection site atrophy
Reports
34
Reporting signal score
116.614

And 21 more, listed on the interactive page.

NCT00000419
clinicaltrials.gov
NCT00000466
clinicaltrials.gov
NCT00000559
clinicaltrials.gov
NCT00026286
clinicaltrials.gov
NCT00420342
clinicaltrials.gov
NCT00543634
clinicaltrials.gov
NCT00745108
clinicaltrials.gov
NCT00004650
clinicaltrials.gov
NCT00083824
clinicaltrials.gov
NCT03097120
clinicaltrials.gov
NCT00002920
clinicaltrials.gov
NCT00003179
clinicaltrials.gov
NCT00033358
clinicaltrials.gov
NCT00739830
clinicaltrials.gov
NCT02228681
clinicaltrials.gov
NCT03567655
clinicaltrials.gov
NCT05255653
clinicaltrials.gov
NCT00030914
clinicaltrials.gov
NCT00044837
clinicaltrials.gov
NCT00807625
clinicaltrials.gov
NCT01421368
clinicaltrials.gov
NCT00066157
clinicaltrials.gov
NCT00191113
clinicaltrials.gov
NCT00291369
clinicaltrials.gov
NCT00360490
clinicaltrials.gov

And 14 more, listed on the interactive page.

Dose: 150 mg
Route: Intramuscular
How often: Every 3 months

Administer in gluteal or deltoid muscle
Assess body habitus to determine needle length
Avoid longer than 2-year use unless necessary
Rotate injection sites
Use strict aseptic technique

Hydrogen bond acceptors: 4
Hydrogen bond donors: 0
Polar surface area: 60.44
Calculated partition coefficient (ALogP): 4.66
Calculated partition coefficient (XLogP): 4.1
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 2
Heavy atoms: 28
Molecular formula: C24H34O4
Monoisotopic mass: 386.24570956
Natural product: Yes

0009-0051
0009-0065
0009-0287
0009-0746
0009-4709
0009-7376
0046-1105
0046-1106
0046-1107
0046-1108
0046-2575
0548-5400
0548-5701
0555-0779
0555-0872
0555-0873
24201-150
51655-520
54348-805
55150-329
55150-330
55289-160
60687-105
62756-090
62756-091

And 28 more, listed on the interactive page.

Recorded assays: 3,331
Active assays: 317

Confirmatory
Other
Screening
Summary

Contraceptive Agents, Hormonal
id.nlm.nih.gov
Contraceptive Agents, Female
id.nlm.nih.gov
Contraceptive Agents, Male
id.nlm.nih.gov
Antineoplastic Agents, Hormonal
id.nlm.nih.gov

Related records

Trials (680)

"Stair Step Study"
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate
A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)
A Clinical Phase I Study on GIC-1001 in Healthy Volunteers
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
A Clinical Study of RSS0343 in Healthy Subjects
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor
A Clinical Study of TQB3824 in Subjects With Advanced Cancer
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
A Clinical Study of ZL-85FA Tablets
A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants

Approved for (5)

In development for (21)

Alzheimer disease Phase 2
Bone disorder Phase 3
Breast cancer Phase 2
Cardiovascular disorder Phase 3
Coronary artery disorder Phase 3
Diabetes mellitus Phase 3
Endometrial cancer Phase 3
Endometrial carcinoma Phase 3
Heart disorder Phase 3
HIV infectious disease Phase 2
Hypertensive disorder Phase 3
Infertility disorder Phase 3
Kidney cancer Phase 3
Myocardial ischemia Phase 3
Osteoporosis Phase 3
Premature ovarian failure 1 Phase 2
Prostate adenocarcinoma Phase 3
Sleep apnea syndrome Phase 2
Systemic lupus erythematosus Phase 3
Thrombotic disease Phase 3

Targets (1)

PGR Progesterone receptor agonist

Medroxyprogesterone acetate

Development status

Names and chemistry

Brand names (40)

Other names (88)

Identifiers

ATC classification codes (3)

RxNorm IDs (RxCUI) (2)

Regulatory information

United States

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (34)

Open Targets indications (57)

Warnings (6)

Open Targets warnings (6)

Reported adverse events (46)

Trial references (39)

Dosing

Conditions of use (5)

Chemical properties

National Drug Codes

Evidence counts

Active assay types (4)

Pharmacologic actions

Related records

Trials (680)

Approved for (5)

In development for (21)

Targets (1)